Oculis secures Privosegtor asset from Accure Therapeutics, strengthening its neuro-ophthalmology pipeline and market positioning
Executive summary: Oculis Holding AG signed an asset purchase agreement with Accure Therapeutics to acquire Privosegtor, the lead candidate for treating neuro-ophthalmic diseases such as optic neuritis. The deal strengthens Oculis’ proprietary pipeline, enhances its competitive position in neuro-ophthalmology, and reduces dependency on external collaborations for late-stage assets.
Who is involved: Oculis Holding AG (Nasdaq: OCS), Accure Therapeutics (S.L.), and Privosegtor as the acquired asset.
Likely next: Regulatory filings for the transfer of Privosegtor, initiation of Phase 3 trials by Oculis, and potential disclosure of financial terms including upfront, milestone, and royalty payments.
Oculis Holding AG has entered into an asset purchase agreement with Accure Therapeutics to acquire Privosegtor, its lead clinical candidate for neuro-ophthalmic indications. The transaction, announced on August 10, 2026, includes global development, regulatory, and commercial rights to Privosegtor, which is currently in Phase 2 development for optic neuritis and other neuro-inflammatory eye conditions. This acquisition accelerates Oculis’ strategy to build a focused portfolio in neuro-ophthalmology, reducing reliance on external partnerships and increasing control over a potentially high-value asset. The move reflects a broader trend of mid-sized biopharma companies in-licensing or acquiring niche therapeutic candidates to de-risk pipelines and enhance standalone valuation.
Timeline
- — Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company (GlobeNewswire)
Analysis — what this means
Likely next events
- Oculis to disclose financial terms of the Privosegtor acquisition by Q4 2026
- Initiation of Phase 3 clinical trials for Privosegtor in optic neuritis expected in H1 2027
- Accure Therapeutics to focus on preclinical pipeline following divestment of lead asset
Sectors affected
- Neuro-ophthalmology therapeutics
- Biopharmaceutical asset acquisitions
- Phase 2 to Phase 3 clinical transition services
Regulatory implications
- FDA and EMA will require updated INDs and CTAs reflecting Oculis as sponsor for Privosegtor
- Transfer of GMP manufacturing and pharmacovigilance responsibilities to Oculis under ICH Q10 and GVP guidelines
- Potential orphan drug designation review for Privosegtor in ischemic optic neuropathy (if pursued)
Historical parallels
- Novartis’ 2020 acquisition of Paducemab from Molecular Partners for ophthalmic use (similar in-licensing of Phase 2 asset)
- Roche’s 2019 purchase of rights to faricimab from Roche/Genentech internal pipeline (internalization of late-stage asset)
- Alder BioPharmaceuticals’ 2018 sale of eptinezumab to Lundbeck (divestment of non-core neuro asset to focus)
Sources
Related cases
- Grundig unveils a new premium appliance lineup at IFA 2026, marking the start of a deeper strategic partnership phase
- Tezspire’s positive Phase 3 eosinophilic esophagitis data open a new growth avenue for the asthma biologic
- Astellas initiates Phase 3 trial of ASP2138 for CLDN18.2-positive gastric cancer, advancing its oncology pipeline
- Brii Biosciences shares interim results highlighting HBV cure progress and vaccine advancement backed by a solid cash position
- Charbone's electrolyzer delivery to Sorel-Tracy advances its Phase 1B green hydrogen project, moving the company closer to commercial production
- Cyprus is technically ready to join Schengen, but political hurdles remain as EU states weigh the divided island’s reality